Recent Updates
Recently added Catalysts

Ardelyx, Inc.

ARDXFDA catalysts, PDUFA dates & pipeline intelligence
$3.18
▲ +0.11 · +3.58%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ARDX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.8052W HIGH $8.40
Volume
4.39 M
Value Traded
13.79 M
Short % Float
12.09%
Days to Cover
7.5
+1.6%Week
+2.91%1 Month
-21.09%3 Month
-49.28%6 Month
-11.83%5 Year
-57.86%All Time

Cash Data

Unlock ARDX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
799.36 M
EPS (TTM)
-0.22
P/E Ratio
-
Ent. Value
766.39 M
Total Shares
251.37 M
Float Shares
241.54 M
Insiders
3.91%
Institutions
70.94%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
IBSRELA (tenapanor)
chronic idiopathic constipation (CIC) in adults
Phase 3Small MoleculesGastrointestinal
Unlock every ARDX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ARDX Catalyst Timeline

Dated clinical, regulatory and corporate events for Ardelyx, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Ardelyx, Inc.

376Total events
9Upcoming
75Tier-1 (high impact)
2016 to 2027Coverage

Upcoming catalysts 2

T2Enrollment Complete
Subscribe to view catalyst details
TenapanorApproved
T2Quarterly Update
Subscribe to view catalyst details
TenapanorApproved

Event history 50

●Quarterly UpdateCorporate
Ardelyx reports Q3 2026 financial results with total product revenue of $125.5 million
▲Enrollment CompleteTenapanorApprovedTrial
Enrollment completed ahead of schedule in Phase 3 ACCEL trial of tenapanor in CIC
chronic idiopathic constipation (CIC)source ↗
▲Enrollment CompleteTenapanorApprovedTrial
ACCEL Phase 3 fully enrolled ahead of schedule in adults with CIC
chronic idiopathic constipationsource ↗
●Poster PresentationTenapanorApprovedPresentation
Poster: Morbidity and Mortality Risks Associated with Cumulative Hyperphosphatemia in a Contemporary Cohort of US Dialysis Patients
hyperphosphatemia in US dialysis patientssource ↗
▲RWE DataTenapanorApprovedClinical Data
Real-world data presented at ASN Kidney Week 2026 showing serum phosphate reductions after XPHOZAH initiation
hyperphosphatemia in adults on dialysissource ↗
●Poster PresentationTenapanorApprovedPresentation
Poster #P5352: Design and rationale of Phase 3, 26-week randomized controlled tenapanor study in CIC
Chronic Idiopathic Constipation (CIC)source ↗
●R&D DayTenapanorApprovedPresentation
Ardelyx-sponsored Product Theater 'Expanding IBS-C Care with a First-in-Class Treatment' at ACG 2026
Irritable Bowel Syndrome with Constipation (IBS-C)source ↗
▲Poster PresentationTenapanorApprovedPresentation
Poster #P3082: GI-HCRU decreases following tenapanor initiation in IBS-C (real-world analysis)
Irritable Bowel Syndrome with Constipation (IBS-C)source ↗
▲RWE DataTenapanorApprovedClinical Data
Real-world data show reduced GI-related healthcare resource utilization after IBSRELA (tenapanor) initiation
Irritable Bowel Syndrome with Constipation (IBS-C)source ↗
●AbstractTenapanorApprovedPresentation
Three ASN Kidney Week 2026 abstracts on hyperphosphatemia and tenapanor available on ASN website
hyperphosphatemiasource ↗
Unlock the full ARDX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ARDX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-10-25XPHOZAH® (tenapanor) Phase 3 data presentation Phase 3
Unlock 8 more ARDX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 22%
Micro Cap
(rank 160 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
IBSRELA
XPHOZAH
Showing 9 of 12 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Tenapanor Small MoleculesNCT07382167Chronic Idiopathic Constipation (CIC)Phase 3 RECRUITING 692Jun 4, 2027
Tenapanor Small MoleculesMarketedNCT06553547Irritable Bowel Syndrome With Constipation (IBS-C)Approved COMPLETED 402Jul 7, 2026
Tenapanor Small MoleculesMarketedNCT02081534HyperphosphatemiaApproved COMPLETED 2,176Nov 1, 2014
Tenapanor Small MoleculesMarketedNCT02686138Constipation Predominant Irritable Bowel SyndromeApproved COMPLETED 1,867Oct 1, 2017
Tenapanor Small MoleculesMarketedNCT01847092Chronic Kidney DiseaseApproved COMPLETED 154Apr 1, 2015
Tenapanor Small MoleculesNot countedNCT01764854End Stage Renal DiseasePhase 2 COMPLETED 88Oct 1, 2013
Tenapanor Small MoleculesNot countedNCT06203444LactationPhase 1 COMPLETED 7May 30, 2024
RDX013 Small MoleculesCompletedNCT04780841HyperkalemiaPhase 2 COMPLETED 109Mar 3, 2022
RDX5791 Small MoleculesMarketedNCT01340053Constipation Predominant Irritable Bowel SyndromeApproved COMPLETED 186Feb 1, 2012
Unlock the ARDX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ARDX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
IBSRELA Irritable Bowel Syndrome with Constipation (IBS-C)2026-10-124.5 to 3.0Read MoreArdelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-CRead More
Scroll for more · summaries link to the source press release
Unlock every ARDX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ARDX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Hohenleitner SusanOfficer (Chief Financial Officer)Sell -1,558 227,520 held$3.86 08/21/2026
Unlock the full ARDX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
TANG CAPITAL MANAGEMENT LLC 1.4 % 30.94 M 9.05 M
Unlock every fund holding ARDX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ARDX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ARDX ownership
Insider and institutional ownership, quarter by quarter.

ARDX Short Interest

Shares sold short, counted twice a month.

12.09%
Short % of Float
of tradable shares sold short
29.2M
Shares Sold Short
-3.4% vs prior count
7.5 High
Days to Cover
trading days of normal volume to buy every short share back
3.9M
Avg Daily Volume
the average used for days to cover
Unlock ARDX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock ARDX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ARDX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ARDX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ARDX ranks across every disease it competes in

Competitive Position is a premium feature
See how ARDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ARDX News

ARDX
Nov 10, 2026
ARDXConferences/Events

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Ardelyx Inc. will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 17, 2026. The event will be accessible via a live webcast. Ardelyx focuses on innovative medicines and has two approved products, with ongoing Phase 3 development for IBSRELA.

Read more →
ARDX
Nov 3, 2026
ARDXPhases
▲ +8.6%on this news

Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update

Ardelyx reported a total product revenue of $125.5 million for Q3 2026, marking a 19% increase from the previous year. The revenue from IBSRELA reached $96.3 million, growing 23% year-over-year. The company completed enrollment for its Phase 3 ACCEL trial for chronic idiopathic constipation ahead of schedule and maintains a strong cash position of $285.3 million.

Read more →
ARDX
Nov 3, 2026
ARDXPhases

Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation

Ardelyx has fully enrolled patients in the Phase 3 ACCEL trial for IBSRELA (tenapanor) ahead of schedule. This trial aims to evaluate the drug's efficacy for chronic idiopathic constipation in adults, with topline data expected in the second half of 2027. The company emphasizes the need for new treatment options for patients suffering from this condition.

Read more →
ARDX
Oct 23, 2026
ARDXConferences/Events

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders

Ardelyx presented real-world data at ASN Kidney Week 2026 showing XPHOZAH reduced serum phosphate in dialysis patients. The analysis of 1,400 adults found adjusted mean reductions of 0.80 to 1.55 mg/dL at six months. Sixty to 70 percent of patients remained on tenapanor at 180 days. The data reinforce ongoing challenges in managing hyperphosphatemia.

Read more →
ARDX
Oct 20, 2026
ARDXGeneral

Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026

Ardelyx Inc. has announced a conference call scheduled for November 3, 2026, to discuss its third quarter financial results and provide a business update. The call will be accessible via a live webcast, with an archived replay available afterward. Ardelyx continues to focus on developing innovative treatments for unmet medical needs.

Read more →
ARDX
Oct 12, 2026
ARDXConferences/Events

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Ardelyx, Inc. presented real-world data at ACG 2026 showing a significant decrease in gastrointestinal-related healthcare resource utilization after adults with IBS-C started treatment with IBSRELA (tenapanor). The analysis involved 470 patients and indicated a drop in healthcare visits from 4.5 to 3.0 per year. Additional data on IBS-C symptom burden and an ongoing Phase 3 study were also discussed.

Read more →
ARDX
Oct 5, 2026
ARDXConferences/Events

Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026

Ardelyx, Inc. announced the presentation of three abstracts at ASN Kidney Week 2026, focusing on hyperphosphatemia management. The research includes real-world effectiveness of tenapanor, patient perspectives, and morbidity risks associated with hyperphosphatemia. Additionally, an Exhibitor Spotlight session will feature insights on XPHOZAH, a phosphate absorption inhibitor for CKD patients on dialysis.

Read more →
ARDX
Sep 30, 2026
ARDXGeneral

Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards

Ardelyx, Inc. announced its recognition at the 2026 PM360 Trailblazer Awards, where it received multiple honors including Life Sciences Manufacturer CEO of the Year for Mike Raab. The company was also acknowledged for its podcast 'Gut Matters' and the IBSRELA Marketing Team. These awards highlight Ardelyx's commitment to innovation and patient engagement.

Read more →
ARDX
Sep 1, 2026
ARDXConferences/Events

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx Inc. has announced its participation in several upcoming investor conferences in September 2026. The conferences include Citi's Biopharma Back to School Conference, Cantor Global Healthcare Conference, and Morgan Stanley's Global Healthcare Conference, all taking place in New York. The company will provide live webcasts of the fireside chats and has a strong product pipeline.

Read more →
ARDX
Aug 6, 2026
ARDXGeneral
▼ -17.9%on this news

Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update

Ardelyx reported a strong financial performance for Q2 2026, with total product revenue reaching $118.1 million, marking a 31% increase compared to the previous year. The revenue from IBSRELA grew by 33% to $86.2 million, while XPHOZAH also saw a 27% increase to $31.9 million. The company maintains a robust cash position of $281.8 million.

Read more →
ARDX
Jul 23, 2026
ARDXConferences/Events

Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

Ardelyx, Inc. announced a conference call scheduled for August 6, 2026, to discuss its second quarter financial results and provide a business update. The event will be accessible via a live webcast and will include an archived replay. Ardelyx is known for its focus on innovative medicines and has two approved products in the U.S.

Read more →
ARDX
May 19, 2026
ARDXConferences/Events

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026

Ardelyx Inc. announced its participation in the Jefferies Global Healthcare Conference 2026, scheduled for June 3 at 9:55 a.m. ET in New York. The company will engage in a fireside chat, which will be accessible via a live webcast. Ardelyx is known for its innovative medicines and has two approved products in the U.S.

Read more →
ARDX
May 7, 2026
ARDXConferences/Events

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings

Ardelyx presented a data analysis at the NKF Spring Clinical Meetings, showcasing the long-term safety of XPHOZAH (tenapanor) for managing serum phosphorus in chronic kidney disease patients on dialysis. The analysis indicated no clinically meaningful changes in serum electrolytes, reinforcing the drug's effectiveness. A peer exchange session will further discuss XPHOZAH's mechanism and safety data.

Read more →
ARDX
Apr 30, 2026
ARDXGeneral
▲ +5.3%on this news· ran to +19% by day 3

Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update

Ardelyx Inc. reported its financial results for Q1 2026, highlighting a significant increase in total product revenue and continued robust growth for IBSRELA. The company's revenue for IBSRELA amounted to $70.1 million, driven by increased prescription demand. Despite a strong financial position, Ardelyx reported a net loss of $37.6 million during the quarter. The company is focused on advancing its pipeline, including ongoing clinical trials for IBSRELA and the development of the next-generation NHE3 inhibitor, RDX10531.

Read more →
ARDX
Apr 27, 2026
ARDXConferences/Events

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings

Ardelyx, Inc. announced that an abstract detailing the long-term effects of XPHOZAH on serum electrolytes will be presented at the NKF Spring Clinical Meetings in May 2026. XPHOZAH is the first phosphate absorption inhibitor approved for adults with chronic kidney disease on dialysis. The company will also sponsor a peer exchange discussing XPHOZAH's efficacy and safety.

Read more →
ARDX
Apr 23, 2026
ARDXConferences/Events

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

Ardelyx, Inc. announced that an abstract exploring treatment patterns for irritable bowel syndrome with constipation (IBS-C) has been accepted for a poster presentation at the Digestive Disease Week Conference 2026. The company will also sponsor a Product Theater discussing IBS-C management strategies. IBSRELA, Ardelyx's treatment for IBS-C, has shown promise in improving symptoms.

Read more →
ARDX
Apr 20, 2026
ARDXGeneral

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

Ardelyx, Inc. has appointed Felecia W. Ettenberg as Chief Legal Officer, succeeding Elizabeth Grammer. Ettenberg brings over 25 years of legal experience in the biopharmaceutical sector, including a significant tenure at Bristol Myers Squibb. The company aims to leverage her expertise to enhance its legal, compliance, and regulatory operations while continuing to focus on patient needs.

Read more →
ARDX
Apr 16, 2026
ARDXGeneral

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

Ardelyx, Inc. announced a conference call for April 30, 2026, to discuss its first quarter financial results and provide a business update. The event will be accessible via a live webcast on the company's website. Ardelyx is known for its innovative medicines, including two approved products and ongoing Phase 3 development.

Read more →
ARDX
Apr 1, 2026
ARDXGeneral

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Ardelyx, Inc. has appointed Dr. Rajani Dinavahi as Chief Medical Officer. With over 20 years of experience in various therapeutic areas, she aims to strengthen the company's pipeline and enhance its medical capabilities. Dr. Dinavahi expressed enthusiasm about joining Ardelyx during a pivotal time for the company.

Read more →
ARDX
Mar 12, 2026
ARDXGeneral
▼ -5.5%on this news

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Ardelyx, Inc. announced the recipients of the 2026 Derek Forfang Patient Advocate Award, honoring individuals who have significantly contributed to advocating for kidney disease patients. Established in 2025, the award commemorates Derek Forfang, a dedicated advocate who passed away due to chronic kidney disease. The recipients include notable figures like Edward Drake II and Markesha Grayson, each recognized for their impactful work in educating and supporting communities. The award presentation will take place at the National Kidney Foundation's Spring Clinical Meetings in New Orleans.

Read more →

About Ardelyx, Inc.

Fremont, CA 489 employees ardelyx.com
Headquarters34175 ARDENWOOD BLVD., FREMONT, CA, 94555
Founded2007
BIOPHARMAWATCH ELITE
Trade the next ARDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime